Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...
At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...
The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback